SUMMARIZE WEEK 13B-McGonigle-Licensing format.pdf & 14A: Howland- Foundations and Nonprofits
Also write a 2 paragraph summary regarding 2 prompts:
It has become more and more difficult for large pharmaceutical companies to find late-stage development candidates to in-license. This has led to investment in late-stage preclinical and early-stage development candidates. Which segment of the industry is likely to grow the fastest as a consequence of this trend: academic drug discovery, start-up and early stage biotech, or contract research organizations? Briefly explain your rationale.
2.The Nature Biotechnology article on the changing face of corporate venturing (von Krogh, et al.) describes the increasing prevalence and changing nature of corporate venture investing. In the long run, do you think that corporate investment in early stage biotechs will stifle innovation by implementing corporate processes and decision-making or will the additional resources successfully fuel innovation. Include information from the article to support your position.